Clinical Trial Update: IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial update for IMM2902, a HER2/SIRPα bispecific antibody-receptor fusion protein, in patients with HER2-expressing advanced cancers. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Gastric Cancer

Drugs mentioned

• IMM2902

Snippet

Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Conditions: Advanced Solid Tumor, Advanced Breast Cancer | Phase 1 | Status: SUSPENDED